Jefferies lowered the firm’s price target on Progyny to $31 from $40 and keeps a Buy rating on the shares. After updating the firm’s model to reflect Q2 results and updated guidance, the analyst trimmed estimates to reflect the weaker demand in the quarter and takes a more conservative view of the back half of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY: